Home » Topics » BioWorld Science

BioWorld Science
RSS

AzurRx starts phase II RESERVOIR study in patients with COVID-19 GI infection

April 7, 2021

Bridge Biotherapeutics begins phase I/II trial of BBT-176 in EGFR-mutant NSCLC with C797S

April 7, 2021

Study shows neurological or psychiatric diagnoses for 1 in 3 COVID-19 survivors

April 7, 2021

Landos' IND for omilancor in eosinophilic esophagitis cleared in U.S.

April 7, 2021

MfpA protein acts a T-segment mimic to protect DNA gyrase from fluoroquinolones

April 7, 2021

An efficient target deconvolution approach based on highly parallelized CRISPR/Cas9 genome editing

April 7, 2021

Recognify Life Sciences initiates phase IIa trial of RL-007 in CIAS

April 7, 2021

Pfizer's oral SARS-CoV-2 main protease inhibitor PF-07321332 enters phase I

April 7, 2021

Dosing begins in phase I study of the bispecific antibody TJ-L-14B/ABL-503

April 7, 2021

Oryzon announces preclinical collaboration with Seaver Autism Center at Mount Sinai

April 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...